131I治疗先天性甲状腺单叶缺如合并Graves病甲巯咪唑治疗后复发一例

Case of 131I therapy in a patient with congenital absence of single thyroid gland lobe combined with Graves’ disease and recurrence after methimazole therapy

笔者报道了1例131I治疗先天性甲状腺单叶缺如合并Graves病甲巯咪唑治疗后复发的病例，从临床症状、血清学化验、甲状腺超声及颈胸部SPECT/CT融合显像等方面分析该病例特点，并通过文献复习加深了对先天性甲状腺单叶缺如合并Graves病的认识。甲状腺单叶缺如合并Graves病患者在规律口服抗甲状腺药物治疗后出现复发，应尽早选择131I治疗。131I治疗仍是先天性甲状腺单叶缺如伴Graves病甲巯咪唑治疗后复发患者较为理想的方法。

We report a case of 131I therapy in a patient with congenital absence of single thyroid gland lobe combined with Graves’ disease and recurrence after methimazole therapy. We analyzed the characteristics of this case on the basis of clinical symptoms; auxiliary examination, including serological tests, thyroid ultrasound, and SPECT/CT fusion imaging of neck and chest. Understanding about the congenital absence of single thyroid gland lobe combined with Graves’ disease was deepened through literature review. 131I therapy must be employed as early as possible when a patient with congenital absence of single thyroid gland lobe combined with Graves’ disease exhibits recurrence after regular oral antithyroid drug therapy. 131I therapy is still an ideal method for patients with congenital absence of single thyroid gland lobe combined with Graves’ disease and recurrence after methimazole therapy.